In addition to suppressing prostate cancer, auraptene also reportedly suppresses the cell viability and angiogenesis of breast cancer cells by downregulating expressions of genes related to angiogenesis, such as vascular endothelial growth factor (VEGF) and VEGF Receptor 2 [42]. Here, VEGFA is linked to prostate cancer.